Jianfeng Group Pro 2015-007 (Jianfeng Group Daily Related Party Transaction Announcement)
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2015-007
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Regular Related Party Transaction Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Basic Information of 1. Daily Related Party Transactions
Review Procedures for Implementation of (I) Daily Related Party Transactions
Jinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinhua Pharmaceutical Company") purchases drugs from related party Tianjin Tianshili Pharmaceutical Marketing Group Co., Ltd. (hereinafter referred to as "Tianshili Marketing Group"). It is estimated that the purchase amount in 2015 will be between 0.5 and 5% of the company's audited net assets at the end of 2014 (no more than 103.0351 million yuan). Therefore, this related party transaction needs to be submitted to the board of directors for deliberation, but does not need to be submitted to the general meeting of shareholders for deliberation.
On April 17, 2015, the company held the second meeting of the ninth board of directors. All nine directors of the company attended the meeting in person. The related directors Mr. Jiang Xiaomeng and Mr. Du Zihong avoided voting on the proposal, which complied with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made were legal and effective. After deliberation and voting, the board of directors deliberated and passed the daily related party transaction proposal with 7 votes in favor, 0 votes against and 0 abstention.
The independent directors of the company reviewed the matter in advance and agreed to submit the proposal to the second meeting of the ninth board of directors of the company for deliberation. The independent directors of the company expressed their independent opinions on the adoption of the proposal by the board of directors, and believed that the formation of the resolution complied with the "Company Law", the company's "Articles of Association" and other relevant provisions, and did not harm the interests of small and medium shareholders.
Forecast and Implementation of (II)'s Last Daily Related Party Transaction
The Company issued a public announcement on April 15, 2014. It is estimated that the amount of drugs purchased by Jinhua Pharmaceutical Company from Tianshili Marketing Group in 2014 will be between 0.5 and 5% (between 8.685 million yuan and 86.8499 million yuan) of the Company's audited net assets at the end of 2013. The actual amount incurred in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions, which did not exceed the expected range.
2. Related Party Introduction and Association Relationship
(I) the basic situation of related parties.
1. Jinhua Pharmaceutical Company: Established in January 1994, its domicile is located at 1180 Huancheng East Road, Jinhua City, its legal representative is Jin Xuecai, and its registered capital is 22 million yuan, of which: the company accounts for 10%, Zhejiang Jianfeng Pharmaceutical Co., Ltd., its holding subsidiary, accounts for 90%, and its main business is drug management. Wholesale and retail of prepackaged food; dangerous chemicals and medical devices; chemical reagents (except dangerous goods); glass and products; textiles, clothing and household daily necessities (except dangerous goods); fitness equipment supplies; computers, software and auxiliary equipment; wholesale and retail of teaching molds; exhibition services; medical information services; branches operate with valid certificates: purchase and processing of traditional Chinese medicine. The drug business license mainly includes: sales of proprietary Chinese medicines, Chinese medicinal materials, Chinese medicinal tablets, chemical preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, etc. The audited net profit for 2014 was 6.5056 million yuan, the net assets at the end of 2014 was 73.169 million yuan, and the liabilities were 237.9614 million yuan.
2, Tianshili Marketing Group: The company was established in 1999 February. The company's domicile is Tianshili Modern Chinese Medicine City, Xinyibai Avenue, Beichen Science and Technology Park, Tianjin, with its legal representative Yan Kaijing and registered capital of 25900 yuan, the business scope is the wholesale of Chinese herbal pieces, Chinese medicinal materials, Chinese patent medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, biological products, and diagnostic drugs; chemical raw materials ( except hazardous chemicals and precursor drugs ) , Wholesale and retail of cosmetics, daily chemical products, packaging materials and containers, plastic products, molds, and plastic raw materials; health food (hard capsules, soft capsules, granules, tablets, oral liquids, tea bags, health wine) wholesale and retail; disposable sterile syringes (needles), infusion sets (needles), corneal contact lenses and nursing solutions, medical polymer materials and products, physical therapy and rehabilitation equipment, medical hygiene materials and dressings, Chinese medicine equipment, general diagnosis equipment, Ward care equipment and appliances, household blood glucose meters and test strips, pregnancy diagnosis test strips, condoms wholesale; self-employed and agent of all kinds of goods and technology import and export business, but the state restricts the company to operate or prohibits the import and export of goods and technology, operating feed processing and "three to one supplement " business, operating trade and re-export trade, pre-packaged food wholesale and retail. The net profit attributable to the parent company in 2014 was 16,080.14 yuan, The net assets attributable to the parent company at the end of 2014 were 9,234.05 yuan, and the liabilities were 482,239.84 yuan.
The relationship between the (II) and the listed company
Because Tianshili Marketing Group is the holding subsidiary of Tianshili Pharmaceutical Group Co., Ltd., and Tianshili Pharmaceutical Group Co., Ltd. is the holding subsidiary of Tianshili Holding Group Co., Ltd. (hereinafter referred to as "Tianshili Group"), tasly Group is an associate of the Company and the Company has two directors who are also directors of Tasly Group, so Jinhua Pharmaceutical Company is related to Tasly Marketing Group.
(III) The amount of related party transactions in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions. The implementation was good and there were no disputes.
Main Contents and Pricing Policy of 3. Related Party Transaction
Jinhua Pharmaceutical Company plans to continue to purchase drugs from Tianshili Marketing Group for sale this year. The main contents of this related party transaction are as follows:
(1) Transaction Target: Compound Danshen Dripping Pills, Yangxue Qingnao Granules, etc.
(2) Transaction Price: Agreement Price.
(3) settlement method: full payment according to the sales amount of last month.
(4) Agreement Validity Period: The validity period of the agreement signed by the above-mentioned related parties is 1 year from the date of signature by the legal representatives or authorized representatives of both parties.
(5) Other matters: If there is a major change in the content of this related party transaction during the implementation of the agreement, the company will disclose it in accordance with relevant regulations, and investors are requested to pay attention.
Purpose of 4. Related Party Transaction and Impact on Listed Companies
This related party transaction is to use Jinhua Pharmaceutical Company's existing sales network in Zhejiang Province to purchase drugs from Tianshili Marketing Group for distribution and sales, thus expanding Jinhua Pharmaceutical Company's business scope, further enhancing the Company's market influence and enhancing the Company's marketing capability. At the same time, Tasly Marketing Group is an indirect holding subsidiary of the Company's associates, and the expansion of its sales channels has increased the scale of corporate sales. The connected transaction will not harm the interests of the Company or the minority shareholders.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 21, 2015
More information
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-31
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-31
The water and soil conservation scheme of Daye Peak Mine passed the review.
The water and soil conservation plan of Jinshan limestone mine and Baiyunsi sand shale mine of Daye Peak Cement Company passed expert review a few days ago. In order to effectively prevent and control soil erosion, protect and rationally utilize water and soil resources, reduce water, drought, wind and sand disasters, and improve the ecological environment, in accordance with the "the People's Republic of China Soil and Water Conservation Law", "Management Measures for Soil and Water Conservation Programs for Development and Construction Projects" and other laws and regulations Relevant technical specifications and the requirements of local management departments, Daye Peak commissioned Daye City Soil and Water Conservation Test Station in May this year to prepare soil and water and soil and soil conservation plans for Jinshan limestone mine. Recently, the water and soil conservation plans of the two mines have been prepared and reviewed by experts. After nearly a day of careful review, the participating experts and leaders gave a high evaluation of the plan, and put forward some suggestions and opinions for improvement. At the same time, they fully affirmed Daye Peak's attitude of attaching great importance to the work of soil and water conservation in the mine, and unanimously agreed that the above two The plan passed the review. The service life of water and soil conservation scheme of Jinshan Limestone Mine and Baiyunsi Sand Shale Mine is 5 years. In the next five years, Daye Peak will entrust water and soil conservation supervision and monitoring, and gradually organize the implementation of prevention and control measures in accordance with the plan. By 2021, Daye Peak will prepare a technical evaluation report based on the implementation of the water and soil conservation plan, check the construction and implementation of responsibilities, evaluate the effect of soil erosion prevention and control, and apply for completion acceptance. (Daye Peak)
2020
07-31
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-30
Spike Pharmaceuticals Enters Infant Drug Market
Jindal Baby Drug Co., Ltd. Established Peak Pharmaceuticals to Enter Infant Drug Market Recently, Zhejiang Jindal Baby Drug Co., Ltd., a Sino-German joint venture controlled by Peak Pharmaceuticals, completed registration. Peak Pharmaceuticals will use this as a basis to introduce German technology and products and develop the infant drug market. Zhejiang Jindel Baby Drug Co., Ltd. was jointly funded by Jianfeng Pharmaceutical, Germany Gefu Pharmaceutical Co., Ltd. and Zhuhai Hengqin Deyunjia International Trade Co., Ltd., with a registered capital of 20 million yuan, of which Jianfeng Pharmaceutical contributed 11 million yuan in cash, accounting for 55% of the registered capital. Gefu Pharmaceuticals invested 5 million yuan in the evaluation of two proprietary technologies of "diazepam suppository" and "acetaminophen suppository, 25% of the registered capital; De Yunjia contributed 4 million yuan in cash, accounting for 20% of the registered capital. The company's registered address is in Jinxi Development Zone, Jinhua City. It will rent the existing factory building of Jianfeng Pharmaceutical Jinxi Pharmaceutical Factory for renovation, and strive to absorb their respective expertise and adopt appropriate advanced technology and scientific management methods. A modern pharmaceutical enterprise focusing on the research and development, production and sales of pharmaceutical preparations for infants and children. In this cooperation, the corresponding products of "diazepam suppository" and "acetaminophen suppository", which Ge Fu pharmaceutical has invested in with proprietary technology evaluation, have been listed in Germany, among which diazepam suppository is a therapeutic drug for anti-anxiety, sleep disorder and muscle tension increase; acetaminophen is used for fever caused by cold or cold, and also for relieving mild to moderate pain. After the establishment of the joint venture company, it will be based on these two know-how.
2020
07-31
Jinhua City People's Congress Leaders Peak Survey
On July 26, Cai Jian, deputy director of the Jinhua Municipal People's Congress, Chen Zhishi, secretary general of the Standing Committee of the National People's Congress, and a group of four people visited Jianfeng to conduct research on the introduction of talents and technological innovation, and to communicate with Jiang Xiaomeng, Yu Jianhong, Huang Jinlong, Xiang Chongping, Lan Xiaolong and other group company leaders conducted in-depth exchanges. (this newspaper reporter)
2020
07-31